Children's National Hospital

The First 1,000 Days: A Window of Opportunity for a Brighter Future for Children

Retrieved on: 
Friday, September 23, 2022

WASHINGTON, Sept. 23, 2022 /PRNewswire/ -- The infant and maternal mortality rates in the US are among the highest of any wealthy country, with glaring racial and ethnic disparities. There is significant room to develop a unifying plan for the right policies and systems to improve nutritional security and well-being for vulnerable families. As part of a special series, sponsored by 1,000 Days of FHI Solutions, that will appear in American Journal of Public Health (AJPH) on October 26, 2022. The full series will present the state of science, research needs, and a policy agenda for optimal maternal and child nutrition in the US.

Key Points: 
  • There is significant room to develop a unifying plan for the right policies and systems to improve nutritional security and well-being for vulnerable families.
  • As part of a special series, sponsored by 1,000 Days of FHI Solutions, that will appear in American Journal of Public Health (AJPH) on October 26, 2022.
  • The full series will present the state of science, research needs, and a policy agenda for optimal maternal and child nutrition in the US.
  • Thus, this journal series brings together papers on these topics during pregnancy, birth, the postpartum period, and early childhood for the US population.

MacKenzie Scott gifts $44 million to Friends of the Children to support its long-term mentoring model

Retrieved on: 
Thursday, August 25, 2022

PORTLAND, Ore., Aug. 25, 2022 /PRNewswire/ -- The national organization Friends of the Children announced today its network received a $44 million gift from philanthropist MacKenzie Scott. Friends of the Children is the only national mentoring program in the country with paid, professional mentors called "Friends" who walk alongside youth for 12+ years, no matter what. This gift offers powerful momentum for the organization to serve thousands more children, many of whom are in—or at risk of entering—foster care. In just eight years, Friends of the Children has grown from five to 26 locations across the U.S., serving urban, rural and Tribal communities.

Key Points: 
  • Friends of the Children is the only national mentoring program in the country with paid, professional mentors called "Friends" who walk alongside youth for 12+ years, no matter what.
  • This gift offers powerful momentum for the organization to serve thousands more children, many of whom are inor at risk of enteringfoster care.
  • "We are honored to kickstart our 30th anniversary of serving children with this extraordinary gift from MacKenzie Scott.
  • Of the $44 million, Friends of the Children National received a $15 million gift and 12 of its chapters received direct gifts totaling $29 million.

Imspex Diagnostics announces BreathSpec® Instrument

Retrieved on: 
Tuesday, August 9, 2022

ABERCYNON, Wales, Aug. 9, 2022 /PRNewswire/ -- Imspex Diagnostics Ltd today announced that it has received CE mark for its BreathSpec® instrument for the detection of COVID-19 using non-invasive breath testing and analysis having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC). 

Key Points: 
  • Breathspec is Imspex's proprietary breath analyzer using a unique combination of gas chromatography (GC) and ion mobility spectrometry (IMS) technologies to deliver fast and accurate results.
  • "This is a global first for breath-based Covid-19 testing and a major step towards our mission to bring breath-based testing into the mainstream" said John McKinley, CEO of Imspex Diagnostics.
  • Imspex is a leader in Breathomics, the non-invasive way to address major healthcare challenges.
  • Breath collection and analysis is carried out using Imspex's lead instrument, BreathSpec.

Pediatric Medical Centers Improve the Efficiency of Investigator-Initiated, Multi-Site, Collaborative Research with TriNetX

Retrieved on: 
Friday, July 29, 2022

Representatives from the participating pediatric medical centers meet monthly to propose and evaluate new collaborative research opportunities, introduce potential co-investigators, and pursue peer-reviewed publications.

Key Points: 
  • Representatives from the participating pediatric medical centers meet monthly to propose and evaluate new collaborative research opportunities, introduce potential co-investigators, and pursue peer-reviewed publications.
  • Additional pediatric medical centers are welcome to join the collaborative and are encouraged to contact TriNetX.
  • "Together, through the Pediatric Collaboratory Network, we hope to catalyze innovative clinical trials and lower the barriers to multi-site, investigator-initiated research."
  • "Participation in the Pediatric Collaboratory Network is open and encouraged for all researchers interested in pediatric research that join the TriNetX global health research network."

Five leading children’s hospitals secure $29M in federal funding to enhance future pandemic readiness

Retrieved on: 
Tuesday, July 19, 2022

, principal investigator of this grant and division chief of Emergency Medicine and medical director of Emergency Preparedness at Childrens National.

Key Points: 
  • , principal investigator of this grant and division chief of Emergency Medicine and medical director of Emergency Preparedness at Childrens National.
  • In September 2021, HRSA launched the Regional PPN by funding five pediatric hospitals to support the planning and preparation of childrens hospitals to respond to a global health threat.
  • Childrens National is home to the Childrens National Research Institute and Sheikh Zayed Institute for Pediatric Surgical Innovation .
  • As a non-profit, Children's National Hospital relies on generous donors to help ensure that every child receives the care they need.

NORD's Living Rare Forum and Rare Impact Awards Highlight Powerful Patient Stories and Community Rock Stars

Retrieved on: 
Thursday, June 30, 2022

CLEVELAND, June 30, 2022 /PRNewswire/ -- This week, the National Organization for Rare Disorders (NORD®) hosted the Living Rare, Living Stronger NORD Patient and Family Forum, NORD's annual family focused conference. 300 enthusiastic attendees from across the globe (and 110 more virtually) convened to share inspiring stories and to forge community connections through networking opportunities.

Key Points: 
  • "I have a rare disease, but I am not my rare disease.
  • Knowing I am able to make an impact on someone else's life in the rare disease community, it keeps me moving forward."
  • The Living Rare Forum continued into the evening with the Rare Impact Awards, a celebration of the outstanding individuals, organizations, and industry innovators and their exceptional work benefiting the rare disease community.
  • There was also a special tribute to NORD's 2020 and 2021 Rare Impact Award honorees, who had been previously celebrated virtually.

Aflac commemorates World Sickle Cell Awareness Day with $100,000 donation to Children's National Hospital for research and treatment enhancements

Retrieved on: 
Monday, June 20, 2022

WASHINGTON, June 19, 2022 /PRNewswire/ -- Highlighting its ongoing commitment to children and families facing sickle cell disease, Aflac, the No. 1 provider of supplemental health insurance in the U.S.1, today announced that the company has made a $100,000 contribution to Children's National Hospital to be used for research and treatment of sickle cell. Aflac also welcomed children with sickle cell disease and their families to an exciting day of baseball at Nationals Park in Washington, D.C., as the hometown Washington Nationals took on the Philadelphia Phillies.

Key Points: 
  • WASHINGTON, June 19, 2022 /PRNewswire/ -- Highlighting its ongoing commitment to children and families facing sickle cell disease, Aflac , the No.
  • 1 provider of supplemental health insurance in the U.S.1, today announced that the company has made a $100,000 contribution to Children's National Hospital to be used for research and treatment of sickle cell.
  • We are pleased to provide a day at the ballpark to celebrate the children, families and caregivers who manage the impact of sickle cell disease every day."
  • We are grateful for Aflac's support financially, and for creating wonderful memories for our families such as the Nationals game on World Sickle Cell Day!"

The Mark Foundation for Cancer Research Awards ~$12 million to Cancer Grand Challenges Team Developing Novel Immunotherapies for Childhood Solid Tumors

Retrieved on: 
Thursday, June 16, 2022

NEW YORK, June 16, 2022 /PRNewswire/ -- The Mark Foundation for Cancer Research today announces a new ~$12 million grant to support a global team developing novel immunotherapies for children with solid tumors through Cancer Grand Challenges, an international funding initiative aiming to answer some of the biggest questions facing cancer research worldwide. With this award, the NexTGen team, led by Professor Catherine Bollard (Children's National Hospital, US) and Dr. Martin Pule (University College London, UK), seeks to build a deeper understanding of childhood brain tumors and sarcomas, leading to the development of effective CAR T-cell therapy treatments for these patients.

Key Points: 
  • NEW YORK, June 16, 2022 /PRNewswire/ -- The Mark Foundation for Cancer Research today announces a new ~$12 milliongrant to support a global team developing novel immunotherapies for children with solid tumors through Cancer Grand Challenges , an international funding initiative aiming to answer some of the biggest questions facing cancer research worldwide.
  • Cancer Grand Challenges sought to address this unmet need by issuing the Solid Tumors in Children Challenge, which tasks researchers with developing novel therapies that take into account the unique biology of childhood tumors.
  • "We're delighted that The Mark Foundation for Cancer Research has partnered with Cancer Grand Challenges to co-fund the team taking on our Solid Tumors in Children Challenge," says David Scott, PhD, Director of Cancer Grand Challenges, Cancer Research UK.
  • In 2022, The Mark Foundation received an additional $500 million commitment to fund cutting-edge cancer research in its first decade.

Children’s National Hospital Catherine Bollard selected to lead global Cancer Grand Challenges team taking on solid tumors in children

Retrieved on: 
Thursday, June 16, 2022

, director of the Center for Cancer and Immunology Research at Childrens National Hospital, has been selected to receive a $25m Cancer Grand Challenges award to tackle solid tumors in children.

Key Points: 
  • , director of the Center for Cancer and Immunology Research at Childrens National Hospital, has been selected to receive a $25m Cancer Grand Challenges award to tackle solid tumors in children.
  • With our Cancer Grand Challenge, we hope to bring next-generation CAR T-cell therapies to children with solid tumors, said Dr. Bollard.
  • The Cancer Grand Challenges NexTGen team, announced June 16, 2022, is taking on the initiatives Solid Tumours in Children challenge.
  • The Cancer Grand Challenges NexTGen team is funded by Cancer Research UK, the National Cancer Institute in the U.S. and The Mark Foundation for Cancer Research.

Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

Retrieved on: 
Tuesday, June 7, 2022

BRISBANE, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced promising, final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington’s disease (HD).

Key Points: 
  • Annexons unique approach to tackle HD targets C1q, the initiating molecule of the classical complement pathway, to slow or halt classical complement diseases.
  • ANX005 is designed to fully block C1q and the entire classical complement pathway with the aim of preserving functioning synapses to slow or halt neurodegeneration.
  • The apparent continued stabilization of clinical function over nine months is notable, and generally not expected in a progressive disease like HD.
  • The study enrolled a total of 28 patients, of whom 23 completed both six-months of treatment and subsequent three-month follow-up period.